Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jun;34(6):1154–1159. doi: 10.1128/aac.34.6.1154

Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

G M Eliopoulos 1, K Klimm 1, L B Rice 1, M J Ferraro 1, R C Moellering Jr 1
PMCID: PMC171776  PMID: 2393275

Abstract

The in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent, was evaluated against approximately 600 bacterial isolates. The new drug was 4- to 128-fold more active than ciprofloxacin against a broad range of gram-positive organisms, with the new drug inhibiting 90% of strains of each species except Enterococcus faecium at concentrations of less than or equal to 0.25 microgram/ml. WIN 57273 was four- to eightfold less active than ciprofloxacin against many members of the family Enterobacteriaceae, but the MICs of the new drug for 90% of strains tested (MIC90s) were less than or equal to 8 micrograms/ml (range, 0.25 to 8 micrograms/ml) for all species. Branhamella catarrhalis, Haemophilus influenzae, Neisseria gonorrhoeae, and Legionella spp. were highly susceptible (MIC90s, less than or equal to 0.06 microgram/ml). WIN 57273 demonstrated excellent activity against anaerobes (MIC90s, less than or equal to 0.25 microgram/ml), and the drug was also more active than ciprofloxacin against 30 strains of Mycobacterium avium-M. intracellulare (MIC, 0.1 to 1.0 microgram/ml). The activity of WIN 57273 against gram-positive organisms was minimally affected by pH and increased at low pH (5.4) against gram-negative organisms. The bactericidal activity of WIN 57273 was demonstrated by time-kill techniques against selected organisms. The frequencies of spontaneous resistance to the new agent were low, but resistant colonies could be selected after serial passage of initially susceptible organisms through incremental concentrations of the drug.

Full text

PDF
1158

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. D., Jr, Eliopoulos G. M., Reiszner E., Moellering R. C., Jr In vitro activities of ICI 194008 and ICI 193428, two new cephem antimicrobial agents. Antimicrob Agents Chemother. 1987 Dec;31(12):1997–2001. doi: 10.1128/aac.31.12.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother. 1989 Apr;23(4):527–535. doi: 10.1093/jac/23.4.527. [DOI] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Moellering A. E., Reiszner E., Moellering R. C., Jr In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother. 1985 Oct;28(4):514–520. doi: 10.1128/aac.28.4.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eliopoulos G. M., Reiszner E., Caputo G. M., Moellering R. C., Jr In vitro activity of CI-934, a new quinolone antimicrobial, against gram-positive bacteria. Diagn Microbiol Infect Dis. 1986 Nov;5(4):341–344. doi: 10.1016/0732-8893(86)90040-4. [DOI] [PubMed] [Google Scholar]
  5. Espinoza A. M., Chin N. X., Novelli A., Neu H. C. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988 May;32(5):663–670. doi: 10.1128/aac.32.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fujimaki K., Noumi T., Saikawa I., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827–833. doi: 10.1128/aac.32.6.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones R. N., Barry A. L. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990 Feb;34(2):306–313. doi: 10.1128/aac.34.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. King A., Boothman C., Phillips I. The in-vitro activity of PD127,391, a new quinolone. J Antimicrob Chemother. 1988 Aug;22(2):135–141. doi: 10.1093/jac/22.2.135. [DOI] [PubMed] [Google Scholar]
  9. Rolston K. V., LeBlanc B., Gooch G., Ho D. H., Bodey G. P. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients. J Antimicrob Chemother. 1989 Mar;23(3):363–371. doi: 10.1093/jac/23.3.363. [DOI] [PubMed] [Google Scholar]
  10. Saito A., Sawatari K., Fukuda Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985 Jul;28(1):15–20. doi: 10.1128/aac.28.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Smith R. P., Baltch A. L., Hammer M. C., Conroy J. V. In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob Agents Chemother. 1988 Sep;32(9):1450–1455. doi: 10.1128/aac.32.9.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Takahata M., Otsuki M., Nishino T. In-vitro and in-vivo activities of T-3262, a new pyridone carboxylic acid. J Antimicrob Chemother. 1988 Aug;22(2):143–154. doi: 10.1093/jac/22.2.143. [DOI] [PubMed] [Google Scholar]
  14. Yajko D. M., Nassos P. S., Hadley W. K. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1987 Oct;31(10):1579–1584. doi: 10.1128/aac.31.10.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zervos M. J., Bacon A. E., 3rd, Patterson J. E., Schaberg D. R., Kauffman C. A. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother. 1988 Jan;21(1):113–115. doi: 10.1093/jac/21.1.113. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES